VTRS trades 19.7% below Wall Street's consensus target of $20.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes VTRS achieves its forward estimates and maintains a stable P/E multiple of 6.8x. This scenario reflects the blended consensus of 13 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Viatris Inc. (VTRS) has a Wall Street consensus price target of $20.50, based on estimates from 13 covering analysts. With the stock currently trading at $17.12, this represents a potential upside of +19.7%. The company has a market capitalization of $19.94B.
Analyst price targets range from a low of $20.00 to a high of $22.00, representing a 10% spread in expectations. The median target of $20.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, VTRS trades at a trailing P/E of -5.7x and forward P/E of 6.8x. Analysts expect EPS to grow +812.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TEVATeva Pharmaceutical Industries Limited | $46.1B | $39.01 | $44.75 | +14.7% | Buy | 19.7x | 46 |
 AMRXAmneal Pharmaceuticals, Inc. | $6.2B | $19.33 | $22.25 | +15.1% | Buy | 19.1x | 17 |
 PRGOPerrigo Company plc | $1.9B | $13.84 | $36.20 | +161.6% | Hold | 6.2x | 36 |
 PFEPfizer Inc. | $160.6B | $28.17 | $28.50 | +1.2% | Hold | 9.5x | 39 |
 MRKMerck & Co., Inc. | $365.8B | $148.11 | $158.12 | +6.8% | Buy | 53.9x | 38 |
 ABBVAbbVie Inc. | $468.7B | $265.30 | $287.08 | +8.2% | Buy | 18.9x | 43 |
 LPTXLeap Therapeutics, Inc. | $65M | $0.77 | — | — | — | — | — |
 MCKMcKesson Corporation | $105.0B | $880.50 | $953.00 | +8.2% | Buy | 19.7x | 31 |
 CAHCardinal Health, Inc. | $51.8B | $221.27 | $273.22 | +23.5% | Buy | 17.6x | 33 |
 CVSCVS Health Corp. | $109.6B | $85.86 | $111.20 | +29.5% | Buy | 10.7x | 41 |
Quick answers to the most common questions about buying VTRS stock.
Viatris Inc. (VTRS) has a consensus 12-month price target of $20.5, implying 19.7% upside from $17.12. The 13 analysts covering VTRS see moderate appreciation potential.
VTRS has a consensus rating of "Hold" based on 13 Wall Street analysts. The rating breakdown is mixed, with 8 Hold ratings making up the largest segment. The consensus 12-month price target of $20.5 implies 19.7% upside from current levels.
With a forward P/E of 6.8034x, VTRS trades at a relatively low valuation. The consensus target of $20.5 implies 19.7% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $22 for VTRS, while the most conservative target is $20. The consensus of $20.5 represents the median expectation. These targets typically reflect 12-month expectations.
VTRS is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 8 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month VTRS stock forecast based on 13 Wall Street analysts shows a consensus price target of $20.5, with estimates ranging from $20 (bear case) to $22 (bull case). The median consensus rating is "Hold".
VTRS trades at a forward P/E ratio of 6.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on VTRS, with a "Hold" consensus rating and $20.5 price target (19.7% upside). 4 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
VTRS analyst price targets range from $20 to $22, a 10% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.